Open AccessCOVID-19 Associated Loss of Smell and Taste Treated with Gabapentin
Author(s) -
Jean-Paul Lucke
Publication year - 2022
Publication title -
annals of clinical and medical case reports
Language(s) - English
Resource type - Journals
ISSN - 2639-8109
DOI - 10.47829/acmcr.2022.81101
Subject(s) - anosmia , taste , gabapentin , covid-19 , medicine , pandemic , taste disorder , audiology , psychology , virology , disease , pathology , alternative medicine , infectious disease (medical specialty) , neuroscience , outbreak
Throughout the COVID-19 Pandemic, the symptoms of loss of smell and taste have been commonly encountered by healthcare professionals, and in fact, have become an important screening tool. By some estimates, 96% of COVID-19 patients experience these symptoms to various degrees [1]. While the exact mechanism of cellular events that lead to loss of smell and taste is largely unknown, research is underway to better understand the process. The senses are usually regained with time but often can take months, and in some instances, be permanent [2]. Nearly one out of ten patients have not fully recovered by two months and treatment options so far are limited [3]. The use of a low dose of Gabapentin could be a possible treatment for anosmia and ageusia in COVID-19 patients.